دورية أكاديمية
أعرض في EDS

Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies

التفاصيل البيبلوغرافية
العنوان: Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
المؤلفون: Richard Burt, Dana Warcel, Adele K. Fielding
المصدر: Human Vaccines & Immunotherapeutics, Vol 15, Iss 3, Pp 594-602 (2019)
بيانات النشر: Taylor & Francis Group, 2019.
سنة النشر: 2019
المجموعة: LCC:Immunologic diseases. Allergy
LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: blinatumomab, acute lymphoblastic leukaemia, b-cell non hodgkin lymphoma, immunotherapeutics, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950
الوصف: Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient’s T cells with CD19-expressing tumour cells. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin’s Lymphoma including in patients who are refractory to chemotherapy. This review summarises the development and design of Blinatumomab, the outcome of clinical studies demonstrating its efficacy and how to manage the administration, practically, including relevant toxicities. We compare and contrast it to other emerging agents for treatment of B-cell malignancies.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2164-5515
2164-554X
21645515
العلاقة: https://doaj.org/toc/2164-5515Test; https://doaj.org/toc/2164-554XTest
DOI: 10.1080/21645515.2018.1540828
الوصول الحر: https://doaj.org/article/bc96208bfea24f84a57ed96f6b758bd0Test
رقم الانضمام: edsdoj.bc96208bfea24f84a57ed96f6b758bd0
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:21645515
2164554X
DOI:10.1080/21645515.2018.1540828